Magainin Pharmaceuticals Inc.
Hambrecht & Quist analyst Timothy Wilson downgraded Magainin Pharmaceuticals Inc. to "hold" from "buy" until the uncertainty over the development of MSI-78 is resolved. MAGN announced last week that the treatment and control groups in its pivotal Phase IIb/III study for impetigo showed the same 75 percent response rate (See April 5 BioCentury Extra